# Exosome therapy

Exosomes are tiny membrane vesicles (30 to 150 nm across) that cells release from an internal sorting system. They carry a cargo of proteins, lipids, mRNAs, microRNAs, and other RNAs that can reprogram the cells that take them up. In aging research, exosomes from young blood or from mesenchymal stem cells (MSC-EVs) have shown rejuvenating effects in rodents, improving heart function, cognition, and tissue repair. So they are proposed as a cell-free alternative to plasma transfusion or stem-cell therapy, with possibly lower immune risk. Their regulatory status is contested. The FDA treats most exosome products as biologics that need an IND for clinical use. And in 2019, it issued a safety alert: exosome products marketed for anti-aging, orthopedics, or hair loss outside clinical trials have not shown safety or efficacy. The clinical evidence so far is mostly small pilot studies and case series; controlled randomized trials in aging are absent. The field also has not standardized how to isolate them, characterize the cargo, measure potency, or dose them. So exosome products sold directly at clinics should be viewed with real caution, especially if marketed to you.

## Sources

- Tan F, Li X, Wang Z, et al.. (2024). Clinical applications of stem cell-derived exosomes. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-023-01704-0

---

_Canonical: https://longevity-switzerland.com/en/glossary/exosome-therapy · Part of Longevity Cities · Updated 2026-06-22_